Deciphera Pharmaceuticals, Inc.

DB:D05 Stock Report

Market Cap: €2.1b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Deciphera Pharmaceuticals Valuation

Is D05 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of D05 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€176.62
Fair Value
86.6% undervalued intrinsic discount
8
Number of Analysts

Below Fair Value: D05 (€23.6) is trading below our estimate of fair value (€176.62)

Significantly Below Fair Value: D05 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for D05?

Key metric: As D05 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for D05. This is calculated by dividing D05's market cap by their current revenue.
What is D05's PS Ratio?
PS Ratio12.7x
SalesUS$174.91m
Market CapUS$2.21b

Price to Sales Ratio vs Peers

How does D05's PS Ratio compare to its peers?

The above table shows the PS ratio for D05 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.7x
FYB Formycon
15.3x24.6%€932.3m
BIO3 Biotest
1.6x3.6%€1.4b
HPHA Heidelberg Pharma
13.1x16.6%€110.9m
2INV 2invest
8.8xn/a€67.8m
D05 Deciphera Pharmaceuticals
12.7x23.6%€2.2b

Price-To-Sales vs Peers: D05 is expensive based on its Price-To-Sales Ratio (12.7x) compared to the peer average (9.5x).

Price to Sales Ratio vs Industry

How does D05's PS Ratio compare vs other companies in the DE Biotechs Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
V9Z Aceragen
0.3x-161.8%US$2.18m
D05 12.7xIndustry Avg. 8.3xNo. of Companies5PS0612182430+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: D05 is expensive based on its Price-To-Sales Ratio (12.7x) compared to the European Biotechs industry average (9.7x).

Price to Sales Ratio vs Fair Ratio

What is D05's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

D05 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio12.7x
Fair PS Ratio1.7x

Price-To-Sales vs Fair Ratio: D05 is expensive based on its Price-To-Sales Ratio (12.7x) compared to the estimated Fair Price-To-Sales Ratio (1.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst D05 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
€25.01
0%
6.8%€27.94€23.84n/a8
Feb ’26n/a
€25.01
0%
6.8%€27.94€23.84n/a8
Jan ’26n/a
€25.01
0%
6.8%€27.94€23.84n/a8
Dec ’25n/a
€25.01
0%
6.8%€27.94€23.84n/a8
Nov ’25n/a
€25.01
0%
6.8%€27.94€23.84n/a8
Oct ’25n/a
€25.01
0%
6.8%€27.94€23.84n/a8
Sep ’25n/a
€25.01
0%
6.8%€27.94€23.84n/a8
Aug ’25n/a
€25.01
0%
6.8%€27.94€23.84n/a8
Jul ’25n/a
€25.01
0%
6.8%€27.94€23.84n/a8
Jun ’25€23.40
€24.79
+6.0%
6.6%€27.85€23.76n/a9
May ’25€23.40
€24.60
+5.1%
8.0%€27.98€21.45n/a9
Apr ’25€14.41
€21.66
+50.4%
30.0%€31.41€8.31n/a11
Mar ’25€15.43
€21.85
+41.7%
30.8%€31.61€8.37n/a10
Feb ’25€13.24
€21.48
+62.2%
30.9%€31.21€8.26n/a10
Jan ’25€14.81
€21.38
+44.4%
30.9%€31.07€8.22n/a10
Dec ’24€11.54
€21.38
+85.4%
30.9%€31.07€8.22n/a10
Nov ’24€11.25
€23.10
+105.3%
28.2%€32.13€8.50n/a9
Oct ’24€12.03
€20.04
+66.6%
27.4%€27.32€8.20n/a9
Sep ’24€12.94
€20.04
+54.9%
27.4%€27.32€8.20n/a9
Aug ’24€12.26
€19.29
+57.4%
30.6%€27.12€8.14n/a9
Jul ’24€12.82
€19.70
+53.8%
30.6%€27.71€8.31n/a9
Jun ’24€12.45
€19.18
+54.1%
29.3%€27.14€8.14€23.4010
May ’24€12.81
€19.92
+55.6%
27.5%€27.80€8.34€23.4010
Apr ’24€13.55
€19.92
+47.0%
27.5%€27.80€8.34€14.4110
Mar ’24€13.52
€20.07
+48.4%
27.5%€28.00€8.40€15.4310
Feb ’24€15.34
€19.79
+29.1%
26.0%€27.49€8.25€13.2410
Analyst Price Target
Consensus Narrative from 8 Analysts
€24.76
Fair Value
4.7% undervalued intrinsic discount
8
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/06/11 15:00
End of Day Share Price 2024/06/11 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Deciphera Pharmaceuticals, Inc. is covered by 17 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarB. Riley Securities, Inc.
Arlinda LeeCanaccord Genuity
Charles DuncanCantor Fitzgerald & Co.